ducovest

PPH:NSD-VanEck Vectors Pharmaceutical ETF (USD)

ETF | Health | NASDAQ Global Market

Last Closing

USD 91.69

Change

+0.21 (+0.23)%

Market Cap

USD 0.25B

Volume

0.11M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors? US Listed Pharmaceutical 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Pharmaceutical Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

Company Website : www.marketvectorsetfs.com

Currency: USD

Country : USA

Inception Date: 20/12/2011

Primary Benchmark: MVIS US Listed Pharmaceutical 25 NR USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: 0.41%

Management Expense Ratio: 0.36 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Symbol Company Name Allocation
LLY Eli Lilly and Company 13.10 %
NVO Novo Nordisk A/S 10.11 %
MRK Merck & Company Inc 5.97 %
JNJ Johnson & Johnson 5.95 %
ABBV AbbVie Inc 5.48 %
NVS Novartis AG ADR 5.05 %
AZN AstraZeneca PLC ADR 4.91 %
BW Babcock & Wilcox Enterprises Inc 4.62 %
MCK McKesson Corporation 4.59 %
Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-01 )

Largest Industry Peers for Health

Symbol Name Mer Price(Change) Market Cap
XLV Health Care Select Sector SPDR.. 0.13 %

-1.10 (-0.76%)

 USD 39.08B
VHT Vanguard Health Care Index Fun.. 0.10 %

-1.88 (-0.71%)

 USD 17.67B
XBI SPDR® S&P Biotech ETF 0.35 %

-0.49 (-0.54%)

 USD 6.65B
IHI iShares U.S. Medical Devices E.. 0.43 %

-0.21 (-0.38%)

 USD 5.20B
IXJ iShares Global Healthcare ETF 0.46 %

-0.52 (-0.56%)

 USD 4.01B
IYH iShares U.S. Healthcare ETF 0.43 %

-0.42 (-0.69%)

 USD 3.31B
FHLC Fidelity® MSCI Health Care In.. 0.08 %

-0.57 (-0.84%)

 USD 3.04B
FXH First Trust Health Care AlphaD.. 0.63 %

-0.42 (-0.40%)

 USD 1.24B
FBT First Trust NYSE Arca Biotechn.. 0.57 %

-0.31 (-0.21%)

 USD 1.11B
IHF iShares U.S. Healthcare Provid.. 0.43 %

-0.32 (-0.62%)

 USD 0.75B

ETFs Containing PPH

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.68% 100% F 82% B
Dividend Return 1.09% 100% F 31% F
Total Return 13.77% 100% F 81% B-
Trailing 12 Months  
Capital Gain 18.26% 100% F 79% B-
Dividend Return 1.98% 100% F 30% F
Total Return 20.24% 100% F 77% C+
Trailing 5 Years  
Capital Gain 53.15% 91% A- 77% C+
Dividend Return 10.48% 100% F 41% F
Total Return 63.63% 100% F 77% C+
Average Annual (5 Year Horizon)  
Capital Gain 8.83% 89% A- 67% D+
Dividend Return 10.59% 89% A- 67% D+
Total Return 1.75% 89% A- 42% F
Risk Return Profile  
Volatility (Standard Deviation) 9.04% 89% A- 88% B+
Risk Adjusted Return 117.06% 100% F 99% N/A
Market Capitalization 0.25B 50% F 48% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.